Latest filing published 01 Mar 2006 for VIROPHARMA INC, €806k.
Insider track record
No signal scores available.
Closed purchases
Not enough history yet: 0 closed purchases, at least 2 are needed.
Purchases by company
Baker Biotech Capital III (GP), LLC: trading record in brief
Filings by Baker Biotech Capital III (GP), LLC span 2 companies, the busiest being Viropharma Inc and Intrabiotics Pharmaceuticals Inc /DE. Over a trading history stretching from 24 February 2006 to 28 February 2006, the count stands at 7 filings.
Both buying and selling appear: 1 purchase worth €149k, against 6 sales worth €3.4M. Sales outweigh purchases by €3.3M. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant.
The latest filing, published on 1 March 2006, reports an open-market sale of €806k in Viropharma Inc. The last purchase on record was published on 28 February 2006, which is 7,559 days ago. Typically, a trade is published a median of 2 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Baker Biotech Capital III (GP), LLC
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 43,922 shares@ US$21.743Common StockSEC:0001144204-06-008351:0
- 44,449 shares@ US$21.7242Common StockSEC:0001144204-06-008351:1
- 9,963 shares@ US$21.5799Common StockSEC:0001144204-06-008351:2
- 184 shares@ US$21.8063Common StockSEC:0001144204-06-008351:3
- 65,192 shares@ US$19.8953Common StockSEC:0001144204-06-008351:4
- 32,063 shares@ US$20.4109Common StockSEC:0001144204-06-008351:5
- 52,661 shares@ US$3.35Common StockSEC:0001144204-06-007973:0Canonical exit: 25 May 2006 (T+90)
7 of 7 declarations